Immune check-point in cervical cancer

F De Felice; C Marchetti; I Palaia; R Ostuni; L Muzii; V Tombolini; P Benedetti Panici

doi:10.1016/j.critrevonc.2018.06.006

Immune check-point in cervical cancer

Crit Rev Oncol Hematol. 2018 Sep:129:40-43. doi: 10.1016/j.critrevonc.2018.06.006. Epub 2018 Jun 18.

Authors

F De Felice¹, C Marchetti², I Palaia³, R Ostuni³, L Muzii³, V Tombolini¹, P Benedetti Panici³

Affiliations

¹ Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy.
² Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy. Electronic address: clamarchetti@libero.it.
³ Department of Gynecological and Obstetrical Sciences and Urological Sciences, "Sapienza" University of Rome, Rome, Italy.

PMID: 30097236
DOI: 10.1016/j.critrevonc.2018.06.006

Abstract

Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.

Keywords: CTLA-4; Cervical cancer; Immune check-point; Immunotherapy; Ipilimumab; Nivolumab; PD-1; Pembrolizumab.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors*
Biomarkers / analysis*
CTLA-4 Antigen / antagonists & inhibitors*
Female
Humans
Immunotherapy / methods*
Patient Selection*
Uterine Cervical Neoplasms / drug therapy*
Uterine Cervical Neoplasms / immunology

Substances

Antibodies, Monoclonal
B7-H1 Antigen
Biomarkers
CD274 protein, human
CTLA-4 Antigen
CTLA4 protein, human